WITHDRAWN: How Has the COVID-19 Pandemic and Lockdown Affected Breslow Thickness in Cutaneous Melanoma?

Aldecoa-Otalora, J Sarriugarte; Pascual, Leire Loidi; Iturriagagoitia, Alicia Córdoba; Bayona, Juan Ignacio Yanguas

doi:10.1016/j.adengl.2021.11.001

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Late diagnosis of melanoma was also reflected in the worse tumor staging of patients diagnosed after the onset of the pandemic. The reduction in the percentage of in situ melanoma diagnosis and the increase in invasive melanoma diagnostic from March 2020 observed in our study is in agreement with what has been published by other authors [25,29,30].…”

Section: Discussionsupporting

confidence: 94%

“…Both studies have also reported an increase in the diagnosis of thick melanomas. In addition, the American study has revealed an increase in the number of mitoses and satellites in the period studied after the declaration of the SARS-CoV-2 pandemic [ 29 , 30 ]. The possible difference between the data reported in different countries may be due to the non-uniform magnitude of the pandemic waves throughout the world, and the results may be influenced by the period analyzed in each series.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma

Martínez-López

Díaz-Calvillo

Cuenca‐Barrales

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Early detection of melanoma is one of the main diagnostic goals of dermatologists worldwide, due to the increasing incidence of the disease in our environment. However, the irruption of the SARS-CoV-2 pandemic has posed a challenge to global healthcare, forcing systems to focus their resources on the fight against COVID-19. Methods: Retrospective cohort study. The exposed cohort were patients diagnosed with melanoma in the year after the general confinement in Spain (15 March 2020) and the unexposed cohort were patients with melanoma diagnosed in the previous year. Results: 130 patients were included. No differences were observed between demographic characteristics in both cohorts. The mean Breslow of melanoma before the onset of the pandemic was 1.08, increasing to 2.65 in the year after the onset of the pandemic (p < 0.001). On the other hand, the percentage of melanomas in situ decreased from 38.96% to 16.98% in the year after the declaration of the state of alarm in Spain. Conclusions: The SARS-CoV-2 outbreak has led to a reduction in the early diagnosis of melanoma, with an increase in invasive melanomas with poor prognosis histological factors. This could lead to an increase in melanoma-related mortality in the coming years in our environment.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma

Martínez-López

Díaz-Calvillo

Cuenca‐Barrales

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…The study selection process is summarized in Figure 1 . From a total of 466 records, 25 studies were incorporated in our data analysis models [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ].…”

Section: Resultsmentioning

confidence: 99%

A Meta-Analysis on the Impact of the COVID-19 Pandemic on Cutaneous Melanoma Diagnosis in Europe

Seretis

Bounas

Gaitanis

et al. 2022

Cancers

View full text Add to dashboard Cite

The COVID-19 pandemic has been the epicenter of healthcare attention globally for the past two years, and large-scale adaptations in healthcare provision have been required. This study aimed to investigate the impact of the pandemic and the resulting lockdowns on cutaneous melanoma diagnosis and tumor burdens in Europe. A relevant literature search in electronic databases was conducted from inception to September 2022. The inclusion criteria were: controlled studies published in a peer-reviewed journal evaluating cutaneous melanoma in Europe and reporting data on melanoma characteristics from diagnoses. The quality of studies was evaluated using the Cochrane ROBINS-I tool for assessing bias in non-randomized studies. Meta-analysis was conducted utilizing a random effects model to synthesize the data. A total of 25 studies involving 32,231 patients were included in the data analysis models. Statistically significant increases in mean Breslow thickness (0.29 mm (0.03–0.55 mm)), ulceration rates (OR = 1.66 (1.29–2.13)), and resultant tumor staging were observed in the PostCovid group, with subgroup analysis revealing that lockdown-derived data were responsible for this trend. This meta-analysis reported on the impact of COVID-19 restrictions on melanoma diagnosis in Europe, emphasizing the higher tumor burden and disease progression state provoked by healthcare adaptations in the pandemic period.

show abstract

The Epidemiology of Malignant Melanoma during the First Two Years of the COVID-19 Pandemic: A Systematic Review

Toma

Prodan

Reddyreddy

et al. 2022

IJERPH

View full text Add to dashboard Cite

It is hypothesized that the COVID-19 pandemic had a major impact on the epidemiology of malignant melanoma owing to diminished screening, diagnostic, and treatment capacities, resulting in a more advanced stage at initial presentation. The goal of this study is to undertake a systematic analysis of all epidemiological and clinical data on the trends and patient outcomes with malignant melanoma during the ongoing pandemic. Records were identified from PubMed, Cochrane, and Web of Science, selecting a total of 39 articles, narrative reviews, and editorial letters, following the PRISMA guidelines. The vast majority of the studies were published in Europe (28/39), and North America (7/39). A total of 99,860 patients were analyzed during 2020 and 2021 of the COVID-19 pandemic, and it was observed that malignant melanoma TNM staging increased significantly compared to the pre-pandemic period. Before the pandemic, 25.88% of patients had TNM stage II or above, compared to 36.25% during 2020–2021. During the COVID-19 pandemic, the malignant melanoma Breslow depth index grew from 1.59 mm before 2020 to 1.86 mm in 2020 and 2021. Patients decreased by 19.58% in 2020 and 2021 compared to pre-pandemic numbers. The patient–loss ratio indicated lower screening activity and patient addressability to dermatology and plastic surgery departments with skin cancer concerns during the COVID-19 pandemic. This systematic study shows that the identification and management of malignant melanoma during the COVID-19 pandemic faced major challenges which should alert medical systems to the high number of patients with advanced disease stages who may need emergency treatment and become incurable.

show abstract

WITHDRAWN: How Has the COVID-19 Pandemic and Lockdown Affected Breslow Thickness in Cutaneous Melanoma?

Cited by 3 publications

References 5 publications

Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma

Impact of the COVID-19 Pandemic on the Diagnosis and Prognosis of Melanoma

A Meta-Analysis on the Impact of the COVID-19 Pandemic on Cutaneous Melanoma Diagnosis in Europe

The Epidemiology of Malignant Melanoma during the First Two Years of the COVID-19 Pandemic: A Systematic Review

Contact Info

Product

Resources

About